Prostate cancer in Spain: From guidelines to clinical practice

BJU International

Volumn 108, Issue 1, 2011, Pages 61-66

  Alcaraz, Antonio ^a   Burgos, Francisco J ^b   Cõzar, José M ^c   Gõmez Veiga, Francisco ^d   Morote, Juan ^e   Solsona, Eduardo ^f   Unda, Miguel ^g   Carballido, Joaquín ^h  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d Centro Hospitalario Juan Canalejo   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f Instituto Valenciano Oncologico   (Spain)

^g HOSPITAL DE BASURTO   (Spain)

^h HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Castration levels; EAU guidelines; monitoring; prostate cancer; Spain; testosterone

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CONTINUING EDUCATION; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; GOOD CLINICAL PRACTICE; HUMAN; LOCAL ANESTHESIA; MALE; METASTASIS; PATIENT MONITORING; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SPAIN; TESTOSTERONE BLOOD LEVEL; TUMOR BIOPSY;

EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; SPAIN;

EID: 79959313046     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09832.x     Document Type: Article

References (30)

1. Bray F, Sankila R, Ferlay J, Parkin DM,. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166 (Pubitemid 34031832)
2. D'Ambert JE,. Prostate cancer. Lancet 2008; 371: 1710-21
3. Gobierno de España, Centro Nacional de Epidemiología. Mortalidad por capítulo, causa y sexo en España, 2005. Available at:. Accessed May 2010.
4. Lázaro y de Mercado P, Allona A, Leiva O,. Distribution of urologists in Spain: current situation and estimation of future needs using a predictive model. Actas Urol Esp 2003; 27: 569-80 (Pubitemid 37229170)
5. Heidenreich A, Aus G, Bolla M, et al,. EAU Guidelines on Prostate Cancer. Eur Urol 2008; 53: 68-80 (Pubitemid 350166735)
6. Alcaraz A,. Management of prostate cancer: global estrategies. Eur Urol Suppl 2006; 5: 890-9 (Pubitemid 44486098)
7. Krahn M, Naglie G,. The next step in guideline development: incorporating patient preferences. JAMA 2008; 300: 436-8 (Pubitemid 352040257)
8. Dahm P, Yeung LL, Gallucci M, Simone G, Schünemann HJ,. How to use a clinical practice guideline. J Urol 2009; 181: 472-9
9. Heidenreich A, Bolla M, Joniau S, et al,. EAU Guidelines on Prostate Cancer, 2009. Available at:. Accessed May 2010
10. Kattan MW, Zelefsky MJ, Kupelian PA, et al,. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 2003; 21: 4568-71 (Pubitemid 46594028)
11. Thompson IM, Tangen CM, Paradelo J, et al,. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-62
12. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC,. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-65 (Pubitemid 32916759)
13. Kupelian P, Katcher J, Levin H, Zippe C, Klein E,. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996; 48: 249-60 (Pubitemid 26279618)
14. Van den Ouden D, Hop WC, Kranse R, Schröder FH,. Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol 1997; 79: 203-11
15. Amling C, Blute ML, Bergstrahl EJ, Seay TM, Slezak J, Zincke H,. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 101-5 (Pubitemid 30434268)
16. Rosser CJ, Chichakli R, Levy LB, Kuban DA, Smith LG, Pisters LL,. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol 2002; 168: 536-41 (Pubitemid 34793289)
17. Lane TM, Ansell W, Farrugia D, et al,. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004; 73: 117-22 (Pubitemid 39482720)
18. Bouchot O, Lenormand L, Karam G, et al,. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000; 38: 543-9
19. Albrecht W, Collette L, Fava C, et al,. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 2003; 44: 505-11 (Pubitemid 37328623)
20. Schasfoort E, Heathcote P, Lock T, et al,. Intermittent androgen suppression for the treatment of advanced prostate cancer. J Urol 2003; 169 (Suppl. 4): 1483a
21. Calais da Silva FE, Bono AV, Whelan P, et al,. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uro-oncological Group. Eur Urol 2009; 55: 1269-77
22. Loblaw DA, Virgo KS, Nam R, et al,. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 2007; 25: 1596-605 (Pubitemid 46733088)
23. Alcaraz A,. Management of the hormone sensitivity of prostate cancer: where are we now? Eur Urol 2008; 54: 247-51
24. Nair B, Wilt T, McDonald R, Rutks I,. Early versus deferred androgen supression in the treatment of advance prostatic cancer. Cochrane Database Syst Rev 2002; (1): CD003506
25. Studer UE, Hauri D, Hanselmann S, et al,. Immediate versus deferred hormonal therapy for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol 2004; 15: 4109-18 (Pubitemid 41185180)
26. Studer UE, Whelan P, Albrecht W, et al,. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24: 1868-76 (Pubitemid 46638985)
27. Schröder F, Kurth K, Fossa S, et al,. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumour: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. J Urol 2004; 172: 923-7 (Pubitemid 39096424)
28. Oefelein MG, Resnick MI,. Effective testosterone suppression for prostate cancer. Is there a best castration? Urology 2003; 62: 207-13 (Pubitemid 36952063)
29. Morote J, Planas J, Raventõs CX,. The serum testosterone castration level with clinical relevance. Eur Urol 2007; 6 (Suppl. 2): 29, abstract 25
30. Morote J, Orsola A, Planas J, et al,. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 1290-5 (Pubitemid 47368393)